|Bid||8.15 x 800|
|Ask||8.17 x 1200|
|Day's Range||7.84 - 8.21|
|52 Week Range||6.26 - 21.45|
|Beta (3Y Monthly)||0.92|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
It might seem bad, but the worst that can happen when you buy a stock (without leverage) is that its share price goes to zero. But in contrast you can make much more than 100% if the company does well. To wit, the Abeona...
On a per-share basis, the Dallas-based company said it had a loss of 36 cents. The results surpassed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research ...
Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! Zero-debt allows substantial financial flexibility, especially for small-cap companies likeRead More...
Tim Miller has been the CEO of Abeona Therapeutics Inc. (NASDAQ:ABEO) since 2015. This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of Read More...
“Market conditions are changing. The continued rise in interest rates suggests we are in the early stages of a bond bear market, which could intensify as central banks withdraw liquidity. The receding tide of liquidity will start to reveal more rocks beyond what has been exposed in emerging markets so far, and the value of […]
Abeona Therapeutics (ABEO) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.
Abeona Therapeutics Inc. (ABEO) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.
Abeona Therapeutics (ABEO) delivered earnings and revenue surprises of -47.83% and 68.04%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Dallas-based company said it had a loss of 34 cents. The results missed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was ...
If you own shares in Abeona Therapeutics Inc (NASDAQ:ABEO) then it’s worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a measure Read More...
Yesterday, Abeona Therapeutics (ABEO) stock closed at $13, ~75% below its 52-week high of $22.75 on October 11, 2017. This month, Abeona stock has fallen 15% from $15.40 on August 31. Abeona’s 52-week low is $10.50, which it reached on February 15.
Abeona Therapeutics Inc’s (NASDAQ:ABEO): Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. With the latest financial yearRead More...
BioLife Solutions (BLFS) generated a net income of $1.05 million in the second quarter compared to a net loss of $768,212 in the second quarter of 2017. That translates to net income per share of $0.05 in the second quarter. Its net loss per share was $0.06 in the second quarter of 2017.
Abeona Therapeutics (ABEO) delivered earnings and revenue surprises of -56.25% and -54.83%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
The Dallas-based company said it had a loss of 25 cents per share. The results did not meet Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for ...
Abeona Therapeutics (ABEO) needs investors to pay close attention to the stock based on moves in the options market lately.
Abeona Therapeutics Inc (NASDAQ: ABEO ), which employs gene and cell therapy for potential rare disease treatments, has a favorable risk-reward profile, according to Seaport Global Securities. The Analyst ...
Stock investors looking for long-term growth plays in the health care space may seek guidance from Fidelity Fund manager Eddie Yoon, who oversees more than $35 billion in assets and leads the firm's health sector with a team of 12 investment professionals.